Gene therapy · Gene replacement · developed by Krystal Biotech
KB408 is a nebulized, replication-defective HSV-1 vector that delivers a full-length human SERPINA1 gene, which encodes alpha-1 antitrypsin. It is being studied in alpha-1 antitrypsin deficiency.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06049082 | Phase 1 | Alpha 1-Antitrypsin Deficiency | Recruiting | KRYS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Alpha 1-Antitrypsin Deficiency
Updated Oct 18, 2026. Something wrong or missing? Report it on the KRYS page.
See KRYS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KRYS catalysts and pipeline →